Transcriptional activation of FN1 and IL11 by HMGA2 promotes the malignant behavior of colorectal cancer
Transcriptional activation of FN1 and IL11 by HMGA2 promotes the malignant behavior of colorectal cancer
复制标题
HMGA2转录激活FN1和IL11促进结直肠癌的恶性行为
DOI:
10.1093/carcin/bgw029
复制
发表时间:
2016-05-01
期刊:
影响因子:
4.7
通讯作者:
Lai, Maode
中科院分区:
文献类型:
--
作者:
Wu, Jingjing;Wang, Yuhong;Lai, Maode
The oncogenic properties of high-mobility gene group A2 (HMGA2) in colorectal cancer (CRC) were mediated through directly binding to the promoters of IL11 and FN1, transcriptionally activating their expressions and inducing epithelial-mesenchymal transition through a pSTAT3-dependent pathway. HMGA2 and IL11 may predict worse prognosis of CRC.Colorectal cancer (CRC) is the second leading cause of cancer deaths worldwide, and metastasis is the principle reason for its poor prognosis. Overexpression of high-mobility gene group A2 (HMGA2) contributes to the aggressiveness of CRC. However, the underlying molecular mechanism of its overexpression is still elusive. In this study, we showed that ectopic expression of HMGA2 significantly enhanced cell migration and invasion in vitro and promoted tumor growth and distant metastasis in vivo. In contrast, the silencing of HMGA2 produced the opposite effects in vitro and in vivo. Chromatin immunoprecipitation-PCR and luciferase assays revealed that HMGA2 bound directly to the promoters of FN1 and IL11 and significantly induced their transcriptional activities. Moreover, as the direct downstream target of HMGA2, IL11 modulated cell migration and invasion through a pSTAT3-dependent signaling pathway. Furthermore, a strong positive correlation between HMGA2 and IL11 expression was identified in 122 CRC tissues. High IL11 expression was associated with poor differentiation, a large tumor size, lymph node metastasis and low overall survival in CRC patients. Collectively, our data reveal novel insights into the molecular mechanisms underlying HMGA2-mediated CRC metastasis and highlight the possibility of targeting HMGA2 and IL11 for treating CRC patients with metastasis.